Carmelo Graffagnino

Professor of Neurology

Neurology, Neurocritical Care

Duke Box 3824, 0109 Orange Zone - South Clinics, Durham, NC 27710

DUMC 3824, 0109 Orange Zone - South Clinics, Durham, NC 27710

More About This Person

At a Glance

Credentials
1. Education
2. Training & Certifications

Academic Experience
1. Current Appointments & Affiliations
2. Previous Appointments & Affiliations

Expertise
1. Global Scholarship

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition
1. In the News

Professional Activities

Embed Profile Data

Embed Profile Data

Selected Grants

IMPROVE Stroke Care Systems of Care Research Program

Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2018 - 2022

Medtronic Stroke Initiative

ResearchPrincipal Investigator · Awarded by Medtronic Foundation · 2016 - 2022

IMPROVE STROKE

ResearchPrincipal Investigator · Awarded by Chiesi Farmaceutici SPA · 2019 - 2020

A Phase 1B/2. Multiccenter,Doubleblind Placebo-controlled, Randomized, Single-Ascending dose study to assess the safety, Pharmacokinetics and pharmacodynamics of DS-1040B in Subjects with Acute Ischemic Stroke.

Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2016 - 2019

Secondary Stroke Prevention Study comparing Dabigatran vs Acetylsalicylic Acid in patients with Embolic Stroke of Undetermined Source RE-SPECT ESUS

Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2015 - 2019

Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal subarachnoid Hemorrhage

Clinical TrialPrincipal Investigator · Awarded by Edge Therapeutics, Inc · 2016 - 2019

A Phase 2,PlaceboControlled,Randomized,Double-Blind,Parallel-Arm Study to EvaluateEfficacy and Safety of BMS-986141For the Prevention of Recurrent Brain Infarction in Subjects receiving acetylsalicyclic acid(ASA)followingAcute Ischemic Stroke or TIA

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2016 - 2017

A Randomized, Double-Blind, MultiNational Study to Prevent Major Vascular Events with Ticagrelor Compared to Aspirin (ASA) in Patients with Acute Ischaemic Stroke or TIA (SOCRATES)

Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2013 - 2016

Medically ill Patient Assessment of Rivaroxaban versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism RISK (MARINER)

Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2014 - 2016

PivotalPhase3,Prospective,Mutli-center,DoubleBlinded,Randomized,Sham-ControlledTrialto determineTheTherEffectsOfNav guided 1HzRTMS Administered to Contralesional Hemisphere-Adjuvant to task-Oriented Rehabilitation inPts withIschemicorHemorr. Stroke.

Clinical TrialPrincipal Investigator · Awarded by Nexstim, Inc. · 2014 - 2016

Phase 1/2 A Multicenter, Controlled, Randomized, Open-Label, Dose Escalation, Safety. Tolerability and Pharmocokinetic Study Comparing EG-1962 and Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage.

Clinical TrialPrincipal Investigator · Awarded by Edge Therapeutics, Inc · 2013 - 2016

Transition of Care for Acute Stroke and Myocardial Infarction Patients

ResearchPrincipal Investigator · Awarded by Agency for Healthcare Research and Quality · 2010 - 2011

Aging And Cognition After Cardiac Surgery

ResearchCollaborator · Awarded by National Institutes of Health · 1999 - 2004